Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MS at the Limits 2022 | When should DMTs be stopped when treating MS?

Emma Tallantyre, MD, PhD, Cardiff University, Cardiff, UK, discusses the question of when it is appropriate to stop disease-modifying therapy (DMT) in multiple sclerosis (MS) patients. She explains that there have been some recent observational studies that have looked at stopping DMTs, however, patients in these studies have differing reasons for stopping treatment, such as pregnancy, loss of efficacy, or experiencing an adverse event. These studies have also considered predictors for return of disease activity, such as recently active disease in younger patients. Dr Tallantyre also clarifies that certain DMTs have a tendency for a rebound of activity in select patients. There is a need to carry out randomized controlled trials to ascertain when DMTs ought to be stopped. Furthermore, Dr Tallantyre highlights the importance of monitoring patients after stopping DMT in order to quickly identify any return of disease activity before they experience an established worsening of their condition. This interview took place during the 2022 Multiple Sclerosis at the Limits Conference in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


In the last 5 years, Dr Tallantyre has received honorarium for consulting work from Biogen, Janssen, Merck, Novartis, and Roche. She has received travel grants to attend or speak at educational meetings from Biogen, Merck, Roche, Takeda and Novartis.